A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH AND WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Brief description of study

This study is testing if a new treatment works for patients with hepatocellular carcinoma (HCC) that's either very advanced or has spread to other parts of the body. The study includes adults aged 18 and older who haven't had any treatment for this cancer before. We'll compare two groups: one getting atezolizumab, bevacizumab, and tiragolumab, and the other getting atezolizumab, bevacizumab, and receive a fake treatment (placebo). The treatment involves getting liquid medicines through an IV tube every three weeks, and we'll follow the instructions closely. The goal is to find out if this treatment is safe and effective for people with this cancer who haven't been treated before.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.